223 related articles for article (PubMed ID: 1857534)
1. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.
Jespersen B; Jensen JD; Nielsen HK; Lauridsen IN; Andersen MJ; Poulsen JH; Gammelgaard B; Pedersen EB
Nephrol Dial Transplant; 1991; 6(2):98-104. PubMed ID: 1857534
[TBL] [Abstract][Full Text] [Related]
2. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
8. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.
Weinreich T; Passlick-Deetjen J; Ritz E
Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324
[TBL] [Abstract][Full Text] [Related]
9. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
[TBL] [Abstract][Full Text] [Related]
11. Long-term CaCO3 treatment of chronic hemodialysis patients: an attempt to prevent aluminum osteopathy.
Matsubara M; Unagami H; Totsune K; Sato H; Kikuta Y; Ogawa M; Saito T; Yoshinaga K
ASAIO Trans; 1988; 34(3):168-71. PubMed ID: 3196505
[TBL] [Abstract][Full Text] [Related]
12. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
13. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
14. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
15. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients.
Oettinger CW; Oliver JC; Macon EJ
J Am Soc Nephrol; 1992 Oct; 3(4):995-1001. PubMed ID: 1450373
[TBL] [Abstract][Full Text] [Related]
16. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
[TBL] [Abstract][Full Text] [Related]
17. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover.
Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O
Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
19. Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.
Inaba M; Okuno S; Nagayama H; Yamada S; Ishimura E; Imanishi Y; Shoji S
J Ren Nutr; 2015 Mar; 25(2):242-6. PubMed ID: 25556148
[TBL] [Abstract][Full Text] [Related]
20. [Replacement of aluminum-containing phosphate binders by calcium and magnesium carbonates in long-term hemodialysis].
Zellweger U; Zaugg PY; Dambacher M; Binswanger U; Gautschi K; Hany A
Dtsch Med Wochenschr; 1989 Apr; 114(17):659-64. PubMed ID: 2707134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
